News:
Inovio Completes Enrollment of its VGX-3100 Open-label Phase 2 Trial for Treatment of HPV-Related High-Grade Anal Dysplasia
Inovio Pharmaceuticals Reports 2019 Second Quarter Financial Results
Inovio Closes $15 Million Private Placement of Convertible Bonds to Institutional Investors in Korea
Inovio is where
IMMUNO-INGENUITY is making the difference for patients with cancer and infectious diseases.
“At Inovio, the revolutionary power of our technology is superseded only by the dedication, passion, and expertise of the team we have brought together to bring our technology to life for patients in need.”
J. Joseph Kim, Ph.D.
President and CEO
Investor information
Review Inovio’s investor presentation highlighting our science, progress, and key upcoming milestones.
Inovio is focusing on transforming the prevention and treatment of cancer and infectious diseases.
Product pipeline
Inovio has a robust pipeline of product candidates targeting cancer and infectious diseases, with several programs entering late stages of development.
Inovio's technology is IMMUNO-INGENUITY in action
Inovio's activation immunotherapy platform is generating best-in-class immune responses in the fight against cancer and infectious diseases.